News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Macro headwinds test Bitcoin price as $70K crumbles amid US market volatility2Trump filling Democratic seats at SEC, CFTC could advance crypto bill talks, TD Cowen says3Bitcoin price ignores $168M Strategy buy, and falls as Iran tensions escalate
Organigram Bets Big On Europe With Sanity Group Takeover
Finviz·2026/02/18 12:27
Charles River: Fourth Quarter Financial Results Overview
101 finance·2026/02/18 12:21
AI-Generated Code Blunder Sparks Multi-Million Dollar DeFi Breach
Cointurk·2026/02/18 12:12
Uber to invest over $100 million in autonomous vehicle charging amid robotaxi push
101 finance·2026/02/18 12:12
Uber to invest over $100 million in autonomous vehicle charging amid robotaxi push
101 finance·2026/02/18 12:06
Upwork Announces $300 Million Share Repurchase Program
Finviz·2026/02/18 12:03
Advanced Biomed Inc. Announces 1 for 20 Share Consolidation
Finviz·2026/02/18 12:03
Mister Car Wash to Be Taken Private by Leonard Green & Partners for $7.00 Per Share
Finviz·2026/02/18 12:03
Flash
12:17
Spruce Biosciences recently announced that its candidate drug TA-ERT for Sanfilippo syndrome type B (also known as MPS IIIB) received positive feedback during a Type B meeting with the U.S. Food and Drug Administration (FDA).The meeting focused on discussing the clinical development plan for the drug. Both parties reached an important consensus on the subsequent trial protocol, laying a solid foundation for advancing the research and development process of TA-ERT.
12:16
Rosenblatt Securities has upgraded its investment rating for Kunteng Electronics from "Neutral" to "Buy," and has significantly raised its target price from $335 to $360.This rating adjustment reflects the institution's positive outlook on the future growth prospects of KengTeng Electronics. Analysts pointed out that KengTeng Electronics' leading position in the electronic design automation sector, as well as its strategic layout in the fields of artificial intelligence and cloud computing, provide strong momentum for the company's sustained growth. The new target price presents significant upside potential compared to the current stock price, demonstrating the institution's firm confidence in the company's performance.
12:16
Spruce Biosciences recently announced that its candidate drug TA-ERT for Sanfilippo syndrome type B (also known as MPS IIIB) received positive feedback during a Type B meeting with the U.S. Food and Drug Administration (FDA).The meeting focused on discussing the clinical development plan for the drug. Both parties reached an important consensus on the subsequent trial protocol, laying a solid foundation for advancing the research and development process of TA-ERT.
News